JPRN-UMIN000044648已完成未知
Epidemiological Research on SARS-CoV-2 (novel coronavirus) Antibody Positivity Rate among Healthcare Workers at Saitama Medical Center, Jichi Medical University during the COVID-19 Pandemic - Epidemiological Research on SARS-CoV-2 Antibody Positivity Rate among Healthcare Workers
Saitama Medical Center Jichi Medical University0 个研究点目标入组 116 人开始时间: 2021年6月30日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 116
研究概览
简要总结
All tests performed during the research period were negative for SARS-CoV2 antibody
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Those with fever, cough, or respiratory distress at the time of the initial examination, and those who do not consent to the research.
研究者
相似试验
进行中（未招募）
1 期
Etude de phase II, randomisée, testant l'association Nexavar (sorafenib) gemcitabine et oxaliplatine (GEMOX) dans le traitement des carcinomes hépatocellulaires non accessibles à un traitement chirurgical ou locorégional GONEXT - GONEXTCarcinome hépatocellulaire non accessible à une chirurgie ou à une destruction per-cutanée.MedDRA version: 9.1Level: LLTClassification code 10019828Term: Hepatocellular carcinoma non-resectableEUCTR2008-000123-26-FRCentre Val d'Aurelle Paul Lamarque
进行中（未招募）
1 期
Open randomised phase II study evaluating the anti-tumour activity, safety and pharmacology of two different dose regimens of IPH 2101, a human monoclonal anti-KIR antibody, in patients with multiple myeloma in stable partial response after a first line therapyMultiple myelomaEUCTR2009-012136-33-FRInnate Pharma42
尚未招募
2 期
Study to evaluate the response to treatment with the medication pasireotide LAR and the expression of the substances AIP and miR-34a in patients with acromegalyE22.0AcromegalyRBR-29grfmFaculdade de Medicina - Universidade Federal do Rio de Janeiro (UFRJ)
进行中（未招募）
1 期
Prospective, phase II randomized study to compare busulfan-fludarabine reduced-intensity conditioning (RIC) with thiotepa-fludarabine RIC regimen prior to allogeneic transplantation of hematopoietic cells for the treatment of myelofibrosisEUCTR2010-022052-23-ITGITMO GRUPPO ITALIANO TRAPIANTO DI MIDOLLO OSSEO,CELLULE STAMINALI EMOPOIETICHE E TERAPIA CELLULARE - ONLUS60
招募中
2 期
“NALPAC” A NON-COMPARATIVE RANDOMIZED PHASE 2 STUDY, EVALUATING THE EFFICACY OF 5-FU + NALIRI AND 5-FU + NALIRINOX FOR METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA (PDAC), PROGRESSIVE AFTER GEMCITABINE-ABRAXANE OR GEMCITABINE MONOTHERAPY.2024-516336-97-00Groupe Belge D'Oncologie Digestive134